Why the study?
Aging promotes metabolic disorders that impair cardiovascular health, and long noncoding RNAs serve as key regulators of glucose, lipid metabolism, and mitochondrial function involved in these processes.
Key points are not available for this paper at this time.
Design
Review
May inform cardiometabolic therapies targeting lncRNAs; leaves open rigorous mechanistic and clinical validation.
The advancement of medical technology has led not only to an increase in life expectancy but also to a rise in aging-related diseases. Aging promotes metabolic disorders, in turn affecting cardiovascular health. Derailment of biological processes in the pancreas, liver, adipose tissue, and skeletal muscle impairs glucose and lipid metabolism, and mitochondrial function, triggering the development of diabetes and lipid-related disorders that inflict damage on cardiac and vascular tissues. Long noncoding RNAs (lncRNAs) regulate a wide range of biological process and are one of the key factors controlling metabolism and mitochondria. Here, we discuss the versatile function of lncRNAs involved in the metabolic regulation of glucose and lipid, and mitochondrial function, and how the dysregulation of lncRNAs induces the development of various metabolic disorders and their cardiovascular consequences.
No takes yet. Share an insight, caveat, or question.
Juni et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: